FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119632452> ?p ?o ?g. }

• W3119632452 abstract "Dear Editor,We would like to comment on the systematic review by Li et al.(1)The use of steroid hormones in the first trimester is a serious issue as organogenesis takes place at this time and therefore there is the possibility of harm from not only congenital anomalies, but also long-term, and even inter-generational effects. Anyone investigating the use of steroid hormones in the first trimester should remember the diethylstilbestrol legacy of devastating harm. Oestrogen (C18H24O2) and diethylstilbestrol (C18H20O2) have similar molecular composition, but their effects are poles apart. In this review, the authors have combined progesterone with progestogens; however they are not the same, in the same way that oestrogen and diethylstilbestrol are not the same. Vaginal micronized progesterone, which we used in our large and high-quality trials (the PROMISE (2) and PRISM (3) trials), has identical molecular structure to natural progesterone, but the other drugs included in this review do not (Table 1). We chose to study vaginal micronized progesterone, as it is identical in structure to natural progesterone, and the available evidence and expert opinion suggested that this is least likely to cause harm. It is important to note that there is evidence of potential harm from dydrogesterone, particularly congenital heart disease.(4)The authors make a bold statement in the abstract about the effects of dydrogesterone on live birth rate. However, they don’t fully address the weaknesses in the evidence. Therefore, we wish to highlight the significant deficiencies in the two trials that contributed live birth data that led to the assertion of beneficial effects from dydrogesterone. Both studies were single centre, open-label studies without placebo control. El-Zibdeh et al did not randomise participants, but instead allocated patients to dydrogesterone on Saturdays, Mondays and Wednesdays, and to no treatment on Sundays, Tuesdays and Thursdays. The trial by Pandian RU was not just a single-centre, but also a single-author study, with insufficient details of the methods to assess its quality. Thus, the effectiveness evidence from these trials cannot be considered reliable.Approximately 80% (4038 of 5056) of the data used in this systematic review come from our PRISM trial.(3) The PRISM trial is a prospectively-registered, randomised, placebo-controlled, multi-centre trial conducted to the highest standards in the UK. The trial found a 3% increase in live birth rate, but with borderline statistical significance (RR, 1.03; 95% CI, 1.00 to 1.07; P=0.08). A pre-specified subgroup analysis in women with the dual risk factors of current pregnancy bleeding and one or more previous miscarriages found a 5% increase in live birth rate (RR, 1.09; 95% CI, 1.03-1.15; P=0.003). In those with three or more previous miscarriages, a 15% increase in live birth rate was observed (RR, 1.28; 95% CI, 1.08 to 1.51; P=0.004).(3, 5) No short-term safety concerns were identified. Based on these data, our recommendation is to consider vaginal micronized progesterone for women with early pregnancy bleeding and one or more previous miscarriages. As for the role of dydrogesterone, we need not only high-quality, randomised trial evidence of its effects but also credible evidence of its safety. As dydrogesterone is a synthetic progesterone-like drug, i.e. a progestogen but not progesterone, the burden of proof to demonstrate short- and long-term safety rests on those promoting this drug." @default.
• W3119632452 created "2021-01-18" @default.
• W3119632452 creator A5001868446 @default.
• W3119632452 creator A5004965789 @default.
• W3119632452 creator A5005460363 @default.
• W3119632452 creator A5007003090 @default.
• W3119632452 creator A5008499634 @default.
• W3119632452 creator A5011467466 @default.
• W3119632452 creator A5018646147 @default.
• W3119632452 creator A5024423524 @default.
• W3119632452 creator A5030262975 @default.
• W3119632452 creator A5030643368 @default.
• W3119632452 creator A5033184333 @default.
• W3119632452 creator A5039814454 @default.
• W3119632452 creator A5048285653 @default.
• W3119632452 creator A5062657695 @default.
• W3119632452 creator A5078160335 @default.
• W3119632452 creator A5085346363 @default.
• W3119632452 creator A5087495070 @default.
• W3119632452 creator A5089181864 @default.
• W3119632452 date "2020-05-22" @default.
• W3119632452 modified "2023-09-23" @default.
• W3119632452 title "Re: Effect of progestogen for women with threatened miscarriage: a systematic review and meta‐analysis. (First comment on BJOG-19-1550.R1)" @default.
• W3119632452 doi "https://doi.org/10.22541/au.159015493.35679779" @default.
• W3119632452 hasPublicationYear "2020" @default.
• W3119632452 type Work @default.
• W3119632452 sameAs 3119632452 @default.
• W3119632452 citedByCount "1" @default.
• W3119632452 countsByYear W31196324522021 @default.
• W3119632452 crossrefType "posted-content" @default.
• W3119632452 hasAuthorship W3119632452A5001868446 @default.
• W3119632452 hasAuthorship W3119632452A5004965789 @default.
• W3119632452 hasAuthorship W3119632452A5005460363 @default.
• W3119632452 hasAuthorship W3119632452A5007003090 @default.
• W3119632452 hasAuthorship W3119632452A5008499634 @default.
• W3119632452 hasAuthorship W3119632452A5011467466 @default.
• W3119632452 hasAuthorship W3119632452A5018646147 @default.
• W3119632452 hasAuthorship W3119632452A5024423524 @default.
• W3119632452 hasAuthorship W3119632452A5030262975 @default.
• W3119632452 hasAuthorship W3119632452A5030643368 @default.
• W3119632452 hasAuthorship W3119632452A5033184333 @default.
• W3119632452 hasAuthorship W3119632452A5039814454 @default.
• W3119632452 hasAuthorship W3119632452A5048285653 @default.
• W3119632452 hasAuthorship W3119632452A5062657695 @default.
• W3119632452 hasAuthorship W3119632452A5078160335 @default.
• W3119632452 hasAuthorship W3119632452A5085346363 @default.
• W3119632452 hasAuthorship W3119632452A5087495070 @default.
• W3119632452 hasAuthorship W3119632452A5089181864 @default.
• W3119632452 hasBestOaLocation W31196324521 @default.
• W3119632452 hasConcept C126322002 @default.
• W3119632452 hasConcept C131872663 @default.
• W3119632452 hasConcept C2779234561 @default.
• W3119632452 hasConcept C2779245376 @default.
• W3119632452 hasConcept C2780572241 @default.
• W3119632452 hasConcept C54355233 @default.
• W3119632452 hasConcept C71315377 @default.
• W3119632452 hasConcept C71924100 @default.
• W3119632452 hasConcept C86803240 @default.
• W3119632452 hasConcept C95190672 @default.
• W3119632452 hasConceptScore W3119632452C126322002 @default.
• W3119632452 hasConceptScore W3119632452C131872663 @default.
• W3119632452 hasConceptScore W3119632452C2779234561 @default.
• W3119632452 hasConceptScore W3119632452C2779245376 @default.
• W3119632452 hasConceptScore W3119632452C2780572241 @default.
• W3119632452 hasConceptScore W3119632452C54355233 @default.
• W3119632452 hasConceptScore W3119632452C71315377 @default.
• W3119632452 hasConceptScore W3119632452C71924100 @default.
• W3119632452 hasConceptScore W3119632452C86803240 @default.
• W3119632452 hasConceptScore W3119632452C95190672 @default.
• W3119632452 hasLocation W31196324521 @default.
• W3119632452 hasOpenAccess W3119632452 @default.
• W3119632452 hasPrimaryLocation W31196324521 @default.
• W3119632452 hasRelatedWork W1963932479 @default.
• W3119632452 hasRelatedWork W2038453978 @default.
• W3119632452 hasRelatedWork W2048833152 @default.
• W3119632452 hasRelatedWork W2057156863 @default.
• W3119632452 hasRelatedWork W2121096509 @default.
• W3119632452 hasRelatedWork W2611199755 @default.
• W3119632452 hasRelatedWork W2990540110 @default.
• W3119632452 hasRelatedWork W4238238276 @default.
• W3119632452 hasRelatedWork W1755616925 @default.
• W3119632452 hasRelatedWork W2903040050 @default.
• W3119632452 isParatext "false" @default.
• W3119632452 isRetracted "false" @default.
• W3119632452 magId "3119632452" @default.
• W3119632452 workType "article" @default.